OptimizeRx Corp — Director's Dealing 2023

Aug 18, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: OptimizeRx Corp (OPRX)
CIK: 0001448431
Period of Report: 2023-06-07

Reporting Person: Spangler Patrick D (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-06-07	Common Stock	M	4637	—	Acquired	22120	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2023-06-07	Restricted Stock Units	$	M	4637	Disposed		Common Stock (4637)	Direct
2023-06-07	Restricted Stock Units	$	A	10061	Acquired		Common Stock (10061)	Direct

Footnotes

F1: Restricted stock units convert into common stock on a one-for-one basis.

F2: On June 7, 2022 the reporting person was granted 4,637 restricted stock units which vested in full on June 7, 2023.

F3: Each restricted stock unit represents a contingent right to receive one share of OptimizeRx common stock.

F4: The restricted stock units will vest in full on the earlier of the first anniversary of the date of grant or the date of the Company's next annual meeting of shareholders.